AFYX Therapeutics’ Clobetasol Patch Sees Success in Oral Lichen Planus Trial
AFYX Therapeutics has announced that its Rivelin clobetasol (Rivelin-CLO) mucoadhesive patch successfully delivered its corticosteroid in a trial evaluating the device in patients with oral lichen planus.
“This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun-patch technology and confirmed that the drug delivered retained its anti-inflammatory activity,” the company said.
According to AFYX, the device is the first biodegradable oral adhesive patch designed to locally deliver clobetasol, a corticosteroid used for skin conditions, to treat oral lichen planus lesions. It uses electrospinning technology to adhere to the oral cavity for 90 minutes on average and other wet-tissue surfaces for approximately 9.5 hours while delivering a steady dose of clobetasol.